A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
Public ClinicalTrials.gov record NCT05701800. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Randomized, Observer-Blind, Active-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity and Immunogenicity of mRNA-1468, a Candidate Vaccine to Prevent Herpes Zoster (HZ) in Healthy Adults ≥50 Years of Age
Study identification
- NCT ID
- NCT05701800
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Enrollment
- 659 participants
Conditions and interventions
Conditions
Interventions
- Placebo Biological
- Shingrix Biological
- mRNA-1468 Biological
Biological
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 22, 2023
- Primary completion
- Jun 29, 2026
- Completion
- Jun 29, 2026
- Last update posted
- Aug 12, 2025
2023 – 2026
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Velocity Clinical Research - Westlake | Los Angeles | California | 90057 | — |
| Tekton Research, Inc - Longmont Center | Longmont | Colorado | 80501 | — |
| Meridien Research | Lakeland | Florida | 33805 | — |
| Clinical Trials of Florida, LLC | Miami | Florida | 33186 | — |
| Floridian Clinical Research | Miami Lakes | Florida | 33016 | — |
| Florida Pulmonary Research Institute, LLC | Winter Park | Florida | 32789 | — |
| Centricity Research | Columbus | Georgia | 31904 | — |
| Great Lakes | Chicago | Illinois | 60640 | — |
| DM Clinical Research- River Forest | River Forest | Illinois | 60305 | — |
| Meridian Clinical Research - Dakota Dunes | Sioux City | Iowa | 51106 | — |
| Johnson County Clin-Trials (JCCT) | Lenexa | Kansas | 66219 | — |
| NOLA Research Works | New Orleans | Louisiana | 70115 | — |
| Velocity Clinical Research - Medford | Medford | Oregon | 97504 | — |
| DM Clinical Research - Philadelphia | Philadelphia | Pennsylvania | 19107 | — |
| WR-ClinSearch, LLC | Chattanooga | Tennessee | 37421 | — |
| Tekton Research | Austin | Texas | 78745 | — |
| Gadolin Research | Beaumont | Texas | 77702 | — |
| LinQ Research, LLC | Houston | Texas | 77087 | — |
| DM Clinical Research | Tomball | Texas | 77375 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05701800, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 12, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05701800 live on ClinicalTrials.gov.